Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

ClinicalTrials.gov ID: NCT02083250

Public ClinicalTrials.gov record NCT02083250. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Fludarabine/Clofarabine/Busulfan Combined With SAHA in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia

Study identification

NCT ID
NCT02083250
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
M.D. Anderson Cancer Center
Other
Enrollment
70 participants

Conditions and interventions

Interventions

  • Allogeneic Bone Marrow Transplantation Procedure
  • Allogeneic Hematopoietic Stem Cell Transplantation Procedure
  • Anti-Thymocyte Globulin Biological
  • Busulfan Drug
  • Clofarabine Drug
  • Fludarabine Phosphate Drug
  • Peripheral Blood Stem Cell Transplantation Procedure
  • Pharmacological Study Other
  • Vorinostat Drug

Procedure · Biological · Drug + 1 more

Eligibility (public fields only)

Age range
Up to 60 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 5, 2014
Primary completion
Nov 11, 2021
Completion
Nov 11, 2021
Last update posted
Jan 5, 2022

2014 – 2021

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
M D Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02083250, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 5, 2022 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02083250 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →